conect4children is pleased to announce that the third c4c International Multi-Stakeholder Meeting (MSM) will address medical devices in paediatric type I diabetes.

The meeting will be hybrid and will take place on 21 February 2023 ahead of the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Berlin (and virtually). The meeting is being organized with the participation of the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and notifying bodies.

What to expect from the meeting:

  • Definition of unmet medical needs of children with type I diabetes

  • Review medical devices which are available and in development

  • Understanding the current regulatory environment

  • Sharing of current hurdles in the paediatric development of medical devices and in access for children

  • and more

MSM have been conceived with the aim to facilitate dialogue and provide an opportunity for constructive interactions between relevant stakeholders (patients/patient representatives, clinicians, academics, pharmaceutical companies and regulators) on topics requiring open discussion on development of medicines in the best interests of children and adolescents.

The overarching objective of the meeting is to propose a strategy to improve the timely development and access of medical devices for children with type I diabetes, properly addressing paediatric unmet needs, introducing innovative development pathways in the regulatory environment and increasing accessibility for all patients.

The output of the meeting will be a common understanding of the needs, issues and available assets by ALL stakeholders and a proposed strategy and actions to address patients’ needs. 

No regulatory decisions on medical devices will be made during the meeting which will share publicly available information. However, the findings and conclusions of the meeting will pave the way for future development plans and concrete actions.

Following the meeting conclusions, an article will be submitted to a peer reviewed journal in the specialty.

Stakeholders involved in this MSM include: international academic experts in paediatric diabetes, representatives from pharmaceutical and medical device companies developing relevant assets, representatives from regulators (EMA, FDA, Notifying bodies, HTA bodies) and patients, parents and their advocates.

The meeting will be by invitation only, following expression of interest. Interested participants can apply by filling the Expression of Interest form available here

Invited participants will be contacted in due time. For questions please contact: